Entries by Lisa Langbein

A CLINICALLY APPLICABLE CONNECTIVITY SIGNATURE FOR GLIOBLASTOMA INCLUDES THE TUMOR NETWORK DRIVER CHI3L1

Research findings related to UNITE work package A03 Tumor microtubes (TMs) connect glioma cells to a network with considerable relevance for tumor progression and therapy resistance. However, the determination of TM-interconnectivity in individual tumors is challenging and the impact on patient survival unresolved. Here, we establish a connectivity signature from single-cell RNA-sequenced (scRNA-Seq) xenografted primary […]

9. February 2024 by

AUTONOMOUS RHYTHMIC ACTIVITY IN GLIOMA NETWORKS DRIVES BRAIN TUMOR GROWTH

  Research findings related to UNITE work package A01 Diffuse gliomas, particularly glioblastomas, are incurable brain tumours. They are characterized by networks of interconnected brain tumour cells that communicate via Ca2+ transients. However, the networks’ architecture and communication strategy and how these influence tumour biology remain unknown. Here we describe how glioblastoma cell networks include a […]

29. November 2023 by

CANCER NEUROSCIENCE: STATE OF THE FIELD, EMERGING DIRECTIONS

Research findings related to UNITE work package A01 The nervous system governs both ontogeny and oncology. Regulating organogenesis during development, maintaining homeostasis, and promoting plasticity throughout life, the nervous system plays parallel roles in the regulation of cancers. Foundational discoveries have elucidated direct paracrine and electrochemical communication between neurons and cancer cells, as well as indirect interactions through neural effects on the […]

29. November 2023 by

PROGNOSTIC MARKERS OF DNA METHYLATION AND NGS SEQUENCING IN PROGRESSIVE GLIOBLASTOMA FROM THE EORTC-26101 TRIAL

Research findings related to UNITE work package A01 Purpose: The EORTC-26101 study was a randomized phase II and III clinical trial of bevacizumab in combination with lomustine versus lomustine alone in progressive glioblastoma. Other than for progression-free survival (PFS), there was no benefit from addition of bevacizumab for overall survival (OS). However, molecular data allow for […]

29. November 2023 by
,

PHD POSITION – CANCER NEUROSCIENCE OF BRAIN TUMORS (m/f/d)

Primary brain tumors, particularly glioblastoma, grow aggressively and are incurable until today. We have discovered novel mechanisms of tumor biology and treatment resistance that are related to the emerging field of “Cancer Neuroscience”: tumor cells hijack neural machanisms to thrive, and communicate with neurons of the normal brain. Brain tumor resistance against established therapies seems […]

6. September 2023 by

EANO GUIDELINES ON THE DIAGNOSIS AND TREATMENT OF DIFFUSE GLIOMAS OF ADULTHOOD

UNITE  towards clinical implementation In response to major changes in diagnostic algorithms and the publication of mature results from various large clinical trials, the European Association of Neuro-Oncology (EANO) recognized the need to provide updated guidelines for the diagnosis and management of adult patients with diffuse gliomas. Through these evidence-based guidelines, a task force of […]

13. December 2020 by

ArticleIL4I1 IS A METABOLIC IMMUNE CHECKPOINT THAT ACTIVATES THE AHR AND PROMOTES TUMOR PROGRESSION

  Research findings related to UNITE work package C04 Aryl hydrocarbon receptor (AHR) activation by tryptophan (Trp) catabolites enhances tumor malignancy and suppresses anti-tumor immunity. The context specificity of AHR target genes has so far impeded systematic investigation of AHR activity and its upstream enzymes across human cancers. A pan-tissue AHR signature, derived by natural […]

1. September 2020 by